Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets

An Unusual Portfolio Question

Eli Lilly finds itself in a position few pharmaceutical companies have occupied: developing two distinct incretin-based therapies for overlapping indications in obesity and type 2 diabetes. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist already on the market. Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist still in Phase 3 development. Understanding how these two molecules differ — and how Lilly might position them — requires examining their pharmacology, clinical data, and the broader strategic landscape.

Dual vs. Triple Agonism

Tirzepatide activates two receptors: GIP and GLP-1. This dual mechanism produced unprecedented weight loss in the SURMOUNT trials, with mean reductions of up to 22.5% at 72 weeks in adults with obesity.

Retatrutide adds a third target: the glucagon receptor. Preclinical work published by Coskun et al. demonstrated that this triple agonist approach in animal models produced greater weight loss and metabolic improvements than dual agonism alone. The glucagon component is believed to increase energy expenditure primarily through hepatic lipid oxidation and thermogenic pathways, providing a mechanistically distinct contribution beyond appetite suppression and insulin sensitization.

In Phase 2 human data, retatrutide at the 12 mg dose showed 24.2% mean body weight loss at 48 weeks. This has since been confirmed and exceeded in Phase 3: TRIUMPH-4 (December 2025) demonstrated 28.7% mean weight loss at 12 mg and 26.4% at 9 mg over 68 weeks in 445 participants with obesity and knee osteoarthritis, compared to 2.1% on placebo. This Phase 3 result surpasses tirzepatide’s 22.5% at 72 weeks in SURMOUNT-1, now with more comparable treatment durations.

Different Development Timelines

Tirzepatide is years ahead in development. It received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. Its safety and efficacy profile is supported by extensive Phase 3 data across multiple patient populations, including those with heart failure, obstructive sleep apnea, and type 2 diabetes.

Retatrutide is currently in Phase 3 trials, with the first readout (TRIUMPH-4) reported in December 2025 and six additional readouts expected in 2026. Eli Lilly has indicated plans to file a New Drug Application (NDA) in late 2026, placing potential FDA approval in the mid-2027 to early 2028 timeframe — approximately four to five years behind tirzepatide’s initial approvals.

Potential Clinical Differentiation

If both drugs ultimately reach the market for obesity, how might they be differentiated? Several possibilities exist:

• Efficacy magnitude: TRIUMPH-4 Phase 3 data have confirmed that retatrutide produces greater weight loss than tirzepatide (28.7% vs. 22.5%). For patients with severe obesity (BMI > 40) or those who have not achieved target weight loss on existing therapies, this more potent option could fill a clinical need.
• Metabolic effects: The glucagon receptor component may confer distinct benefits on hepatic steatosis and lipid metabolism. Early data suggest retatrutide produces significant reductions in liver fat, which could position it favorably for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
• Tolerability profile: TRIUMPH-4 has provided the first large-scale characterization. Gastrointestinal events are broadly consistent with tirzepatide (nausea 43.2%, diarrhea 33.1%, vomiting 20.9% at 12 mg). A notable new finding is dysesthesia (abnormal skin sensation), which occurred in 20.9% of the 12 mg group versus 0.7% on placebo — a signal not seen with tirzepatide. Discontinuation rates were 18.2% at 12 mg. Whether these tolerability differences prove clinically significant across broader populations will depend on the remaining TRIUMPH readouts.

Portfolio Strategy

From a commercial perspective, Lilly’s dual-product approach may not be as redundant as it appears. The obesity pharmacotherapy market is expected to be large enough to support multiple agents, and different patients may respond differently to dual versus triple agonism. A portfolio approach also hedges development risk — if one molecule encounters unexpected safety signals, the other provides continuity.

There is also the possibility of indication-specific positioning. Tirzepatide may become the established first-line incretin therapy, while retatrutide could be positioned for patients requiring more intensive intervention, or for specific comorbidities where the glucagon component offers additional benefit.

Looking Ahead

The relationship between tirzepatide and retatrutide within Lilly’s pipeline is becoming clearer with TRIUMPH-4. The Phase 3 data confirm that triple agonism delivers meaningfully greater weight loss than dual agonism, supporting the clinical significance of glucagon receptor targeting. With an NDA filing planned for late 2026, Lilly will soon face the commercial question of how to position these two molecules — likely with tirzepatide as the established first-line therapy and retatrutide as the more intensive option for patients requiring greater efficacy or those with specific comorbidities like osteoarthritis or MASLD.